Business Wire

CA-CREATIVE-ARTISTS

17.4.2017 20:06:17 CEST | Business Wire | Press release

Share
Creative Artists Agency Partners with CMC Capital, Creating Alliance of Industry Leaders in World’s Fastest Growing Entertainment Market

Creative Artists Agency (CAA), the world’s leading entertainment and sports agency, has partnered with CMC Capital Partners (CMC), China’s leading investment fund in media and entertainment, Internet and mobile, and lifestyle. The robust partnership includes the formation of CAA China, a world-class media and entertainment platform, and a minority strategic investment by CMC in CAA. Creating alignment throughout the agency, CMC Chairman Li Ruigang will join CAA’s Board of Directors.

Majority-owned by CAA, CAA China combines the expertise and vast resources of CAA with the broad reach and network of CMC in Greater China. CMC’s tremendous market experience in entertainment and sports combined with CAA’s representation of top Chinese talent, in addition to its leadership in film finance, will create a wide spectrum of new business and client opportunities in the swiftly growing Chinese market, ranging from talent representation, endorsements, and sports, to digital media, music, and original content production.

With more than two dozen employees in Beijing, CAA opened its China office in 2005 and has successfully built out its multiplatform approach to the market. The company has been at the center of every major Chinese co-production for the past 10 years and has packaged, sold, or raised financing for more than 75 Chinese-language film projects. CAA's Global Film Finance & Sales Group has directed more than $400 million in Chinese capital into English-language content. In addition, under the leadership of Jonah Greenberg, who runs the agency’s China efforts in motion pictures, CAA represents many of the most accomplished actors, directors, writers, and producers from Mainland China, Taiwan and Hong Kong, including Zhang Yimou, Lin Chi-ling, and Donnie Yen, among others.

“For more than a decade, we have served as a vital bridge to and within the Chinese market, utilizing our deep experience and network to support the work of the region’s best artists and to develop opportunities within the market for international talent,” said CAA President Richard Lovett. “CAA China will supercharge our efforts, from motion pictures, television, endorsements, and brand consulting to sports, live events, digital media, and beyond. CMC, under the leadership of Li Ruigang, has a remarkable record of success in the region, and we are confident that our partnership will yield tremendous results for our clients and future business partners in China.”

“We believe China and the US are the two biggest entertainment markets and play pivotal roles on the global landscape. The partnership not only creates commercial and industry value, but also serves as an innovative force in the evolution of the Chinese media industry,” said CMC Chairman Li Ruigang. “CAA is a prominent institution in the US entertainment and sports sector, which has built its success on systematically and consistently enabling the success of their clients throughout the years. We are immensely excited about the potential possibilities of an enhanced China angle by CMC coupled with the experience and resources of CAA. CMC has been in a highly productive cooperation with CAA under the leadership of Richard Lovett, and we look forward to greater accomplishments in the future.”

Founded by Li in 2010, CMC is a leading investor in media and entertainment, Internet and mobile, and lifestyle sectors in China. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has invested and operated in Greater China, North America, Europe and Asian markets, and has created and supported the growth of many champions and emerging leaders in film, television, animation, kids content, sports, music, fashion, games, location-based entertainment, cinema, digital media, social platform, and entertainment technology. CMC’s previous and current investment and operational portfolio includes IMAX China; Star China, China’s top variety production company; Flagship, a joint venture studio with Warner Bros.; and City Football Group, a football club management company that owns Manchester City Football Club and New York City Football Club. Prior to founding CMC, Li was the Chairman and CEO of Shanghai Media Group (SMG) for more than ten years and successfully transformed SMG from a provincial broadcaster into a leading media conglomerate in China.

“CAA China demonstrates the vision and innovation that has driven CAA’s growth and fueled its ability to stay on the leading edge of industry trends,” said Jim Coulter, co-founder of private equity firm TPG, CAA’s majority shareholder. “CAA has had a significant impact on the Chinese entertainment marketplace by enabling its clients’ success over the past 12 years. We are thrilled with the company’s progress and the value-creation CAA has realized for its shareholders since our investment. With CMC as a meaningfully invested partner, and continuing growth in the Chinese market, the potential for CAA China is limitless.”

Greenberg will continue to lead CAA’s China efforts in motion pictures, working with the existing team in the Beijing office. Roeg Sutherland, Co-Head of CAA’s Global Film Finance and Sales Group, will continue to lead the agency’s film finance business in the market. CAA China will progressively add additional senior management to help expand the business into new entertainment and sports areas.

About Creative Artists Agency

Leading entertainment and sports agency Creative Artists Agency (CAA) represents many of the most successful professionals working in film, television, music, theatre, video games, sports, and digital content, and provides a range of strategic marketing and consulting services to corporate clients. CAA is also a leader in sports, representing more than 1,000 of the world’s top athletes in football, baseball, basketball, hockey, soccer, tennis, Olympics and action sports, and golf, and works in the areas of broadcast rights, corporate marketing initiatives, licensing, and sports properties for sales and sponsorship opportunities.

About CMC

CMC, founded and chaired by Li Ruigang, is China's leading investment and operating platform in media & entertainment, Internet & mobile, and lifestyle, and invests and operates in Greater China, north America, Europe and Asian markets. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has created and supported the growth of many industry leaders in subsectors including film, television, animation, sports, music, fashion, games, advertising, marketing, financial media, location-based entertainment, cinema, online video platforms, OTT, smart TV and social media.

Contact:

Creative Artists Agency
424.288.2000
Michael Mand, Mmand@caa.com
Beth McClinton, Beth.McClinton@caa.com
Missy Davy, Mdavy@caa.com
or
CMC
Jiaming Wu, Jiaming.Wu@cmccap.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye